[1]
|
[1]CABALLERIA L, PERA G, RORDRIGUEZ L, et al.Metabolic syndrome and nonalcoholic fatty liver disease in a Spanish population influence of the diagnostic criteria used[J].Eur J Gastroenterol Hepatol, 2012, 24 (9) :1007-1011.
|
[2]
|
[2]ISSA D, PATEL V, SANYAL A J.Future therapy for non-alcoholic fatty liver disease[J].Liver Int, 2018, 38 (Suppl 1) :56-63.
|
[3]
|
[3]ALBA L M, LINDOR K L.Non-alcoholic fatty liver disease[J].Alimentary Pharmacology&Therapeutics, 2003, 17 (8) :977-986.
|
[4]
|
[4]HU Y, LIU J, DONG X, et al.Clinical study of serum homocysteine and non-alcoholic fatty liver disease in euglycemic patients[J].Med Sci Monit, 2016, 22 (1) :4146-4151.
|
[5]
|
[5]KASAPOGLU B, TURKAY C, YALCIN K S, et al.MTHFR677C/T and 1298A/C mutations and non-alcoholic fatty liver disease[J].Clin Med (Lond) , 2015, 15 (3) :248-251.
|
[6]
|
[6]NIU S, WANG L, HE M, et al.Exendin-4 regulates redox homeostasis in rats fed with high-fat diet[J].Acta BiochimBiophys Sin (Shanghai) , 2015, 47 (6) :397-403.
|
[7]
|
[7] LINDSEI K, SARNA, YAW L, et al.The CBS/CSE system:a potential therapeutic target in NAFLD[J].Physiol Pharmacol, 2015, 93 (1) :1-11.
|
[8]
|
[8] YOUNOSSIZM, KOENIGAB, ABDELATIFDF, et al.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J].Hepatology, 2016, 64 (1) :73-84.
|
[9]
|
[9]DAY C P, JAMES O F.Steatohepatitis:A tale of two"hits"[J].Gastroenterology, 1998, 114 (4) :842-845.
|
[10]
|
[10]FOURET G, GAILLET S, LECOMTE J.20-Week follow-up of hepatic steatosis installationand liver mitochondrial structure and activity and their interrelation in rats fed a high fat high fructose diet[J].Br J Nutr, 2018, 119 (4) :368-380.
|
[11]
|
[11]GUO X F, GAO J L, LI J M, et al.fat-1 mice prevent high fat plus high-sugar diet-induced non-alcoholic fatty liver disease[J].Food Funct, 2017, 8 (11) :4053-4061.
|
[12]
|
[12]FRANCO BROCHADO MJ, DOMENICI F A.Methylenetetrahydrofolatereductase gene polymorphism and serum homocysteine levels in nonalcoholic fatty liver disease[J].Ann Nutr Metab, 2013, 63 (3) :193-199.
|
[13]
|
[13]SARNA L K, SIOW Y L, O K.The CBS/CSE system:a potential therapeutic target in NAFLD[J].Can J Physiol Pharmacol, 2015, 93 (1) :1-11.
|
[14]王雅楠, 李治纲, 张鹏, 等.高同型半胱氨酸血症中肝脏的脂肪变性[J].昆明医科大学学报, 2012, 33 (11) :19-22.
|
[15]
|
[15]ZONG Y, AI Q L, ZHONG L M, et al.Ginsenoside Rg1 attenuates lipopolysaccharide-induced inflammatory responses via the phospholipase C-γ1 signaling pathway in murine BV-2 microglial cells[J].Curr Med Chem, 2012, 19 (5) :770-779.
|
[16]
|
[16]GENG J, PENG W, HUANG Y, et al.Ginsenoside-Rg1from Panaxnotoginseng prevents hepatic fibrosis induced by thioacetamide in rats[J].European Journal of Pharmacology, 2010, 634 (1-3) :162-169.
|
[17]
|
[17]CHEN Z, LI C, YANG C, et al.Lipid regulation effects of raw and processed notoginseng radix et rhizome on steatotic hepatocyte L02 cell[J].Biomed Res Int, 2016, 2016 (29) :2919034.
|